GPT and susceptibility to pneumonia measurement: Eight patients had 10 SAEs in the vedolizumab group considered as treatment related by the study investigator (n = 1 patient each for ventricular tachycardia, aGVHD of the intestine, chronic GVHD, Escherichia bacteremia, pneumonia, pseudomonal pneumonia, viral meningitis, subdural hematoma, increased alanine aminotransferase, and recurrent chronic myeloid leukemia).